US Patent 8,118,802: Claim Scope, Patent Strength, Expiration Risk, and Medical-Connector Landscape

US Patent No. 8,118,802 protects a medical-fluid container connector incorporating a self-sealing membrane with a distinctive T-shaped flange and, when installed, an H-shaped cross-sectional configuration. Its principal enforcement value is structural: the claims target the interaction between the membrane geometry and a two-piece snap-fit connector. The patent is a medical-device patent, not a drug patent, so Orange Book listing, Paragraph IV challenges, biosimilar substitution, and FDA drug exclusivity do not apply.

What does US Patent 8,118,802 protect?

The patent has two independent claim groups:

Claim	Protected subject matter	Claim type
1	Self-sealing membrane installed in a medical-fluid-container connector	Apparatus
9	Two-section connector configured to receive and clamp the membrane	Apparatus
2-8	Specific membrane geometries and elastic-clamping characteristics	Dependent apparatus claims
10-17	Connector and installed-membrane configurations	Dependent apparatus claims

The claims require more than a generic pierceable septum. The claimed structure combines:

A penetrable membrane section.
A peripheral flange.
A T-shaped flange cross-section.
A two-piece connector.
Clamping of the flange between connector sections.
In certain claims, an H-shaped installed cross-section.
In claim 9, a peripheral groove and cooperating peripheral projection that create a snap-in connection.

The patent therefore focuses on membrane retention, connector assembly, sealing behavior, and compatibility with a needle, spike, or other penetrator used to access a medical-fluid container.

How do independent claims 1 and 9 differ?

Claim 1: membrane-centered protection

Claim 1 requires a self-sealing membrane disposed within the connector. The membrane must include:

A penetrable section; and
A flange clamped between the lower and upper connector sections.

The flange must have a generally T-shaped cross-sectional profile. That profile is created by:

An inner segment extending from the boundary of the penetrable section; and
An outer segment extending from the boundary of the inner segment.

The likely infringement question is whether the accused membrane has a flange with two radially distinct structural portions, rather than a single uniform lip or flat gasket.

A membrane that has a central pierceable section but lacks the claimed T-shaped flange may avoid literal infringement of claim 1. A membrane with a T-shaped profile that is not disposed within the claimed connector arrangement may also avoid claim 1, depending on the applicable claim construction.

Claim 9: connector-centered protection

Claim 9 shifts the focus from the membrane to the connector. It requires:

A first connector section with a peripheral groove on an internal wall;
A second connector section with a peripheral projection on an external wall;
A snap-in effect when the projection enters the groove; and
Dimensions that accommodate a self-sealing membrane having a generally H-shaped cross-section.

Claim 9 may be commercially significant because it can reach the connector architecture even when the accused product is sold without the membrane or with a separately supplied membrane. The claim still requires the connector to be structurally configured to accommodate the specified membrane profile.

The phrase "sized and dimensioned to" should be evaluated as a structural limitation, not merely as an intended-use statement. A connector would be more exposed if its groove, projection, cavity, and clamping surfaces physically establish the dimensions required for the claimed H-shaped membrane.

What do dependent claims 2 through 8 add?

Claim 2: elastic deformation

Claim 2 requires the flange to be clamped with elastic deformation between the connector sections. This narrows claim 1 to a sealing arrangement in which compression of the flange produces resilient deformation.

A rigidly captured membrane that is not elastically deformed may present a noninfringement position, although the practical strength of that position would depend on the materials, degree of compression, and claim construction.

Claim 3: H-shaped installed configuration

Claim 3 requires the penetrable section and flange to form a generally H-shaped cross-sectional profile when the membrane is positioned across the connector fluid passageway.

This limitation is important because it evaluates the membrane in its installed state. The H-shaped profile may result from the interaction between the central penetrable section and the opposed flange portions. A product that has a T-shaped flange before assembly but does not produce the claimed H-shaped configuration after installation may avoid claim 3.

Claim 4: dish-shaped penetrable section

Claim 4 requires a generally dish-shaped penetrable section. This limitation may cover a concave or curved membrane section designed to improve resealing after penetration or to control deflection during access.

A flat disk or planar septum may fall outside the literal scope of claim 4, although the exact boundary depends on how "generally dish-shaped" is construed.

Claims 5 through 7: differential flange thickness

These claims establish a dimensional relationship between the inner and outer flange segments:

The inner segment has a thickness no greater than d_inner.
The outer segment has a thickness no greater than d_outer.
d_outer is greater than d_inner.

Claim 6 requires the inner segment surfaces to be separated by the first distance. Claim 7 imposes the corresponding relationship on the outer segment.

This arrangement protects a stepped or differentially thick flange. The outer segment is thicker than the inner segment, which may improve retention, increase resistance to extrusion, or create controlled elastic compression at different radial locations.

The limitation is potentially strong against products with measurable radial thickness differences. It is weaker against designs using continuous tapering, uniform thickness, separate sealing rings, or a flange whose inner and outer regions cannot be cleanly identified.

Claim 8: annular-volume construction

Claim 8 defines the inner and outer flange segments as first and second annular volumes. This claim supports a three-dimensional interpretation of the flange rather than a purely two-dimensional sectional description.

An accused product may be evaluated through CAD data, cross-sectional microscopy, dimensional inspection, or manufacturing drawings. The claim does not appear to require a particular polymer, hardness, sterilization method, or molding process.

What do dependent claims 10 through 17 add?

Claim	Added limitation
10	The connector receives a membrane with a T-shaped flange
11	Inner and outer flange segments have different maximum thicknesses
12	Flange includes inner and outer annular volumes
13	Penetrable section is positioned at the intersection of the two connector sections
14	Penetrable section is generally dish-shaped
15	Penetrable section extends across the connector fluid passageway
16	The claim 15 membrane is generally dish-shaped
17	Membrane is held with elastic deformation between connector sections

Claims 13 and 15 distinguish two possible membrane locations:

At the intersection between the first and second connector sections; or
Across the fluid passageway defined by the connector.

Those positions may be relevant to products in which the membrane is captured at a joint, recessed into one connector half, or positioned directly in the flow path.

What is the strongest infringement theory under US Patent 8,118,802?

The strongest literal-infringement theory would involve a product having all of the following:

A medical-fluid container connector.
Two connector sections joined by a peripheral snap-fit.
An internal groove in one section.
A cooperating external projection in the other section.
A pierceable membrane clamped between the sections.
A T-shaped membrane flange.
An H-shaped installed cross-section.
A thicker outer flange segment than inner segment.
Elastic deformation of the flange during assembly.

Claim 1 provides a direct route against the membrane assembly. Claim 9 provides a separate route against the connector. Claims 3, 5, 8, 11, and 17 add measurable structural limitations that may support infringement analysis but also create design-around opportunities.

How strong is the patent estate based on the supplied claims?

The claim set has moderate structural specificity and potentially meaningful product coverage. Its strength depends on whether competing connectors use the same radial flange architecture.

Strength factor	Assessment
Independent claim coverage	Two independent apparatus claims address both membrane and connector
Structural specificity	High; the claims require defined profiles, grooves, projections, and clamping relationships
Functional breadth	Moderate; the claims do not require a specific drug, fluid, polymer, needle, or container material
Design-around exposure	Moderate to high; changing the retention mechanism or flange profile may avoid literal scope
Manufacturing-process coverage	Limited; the supplied claims do not cover molding, assembly, sterilization, or material composition
Product dependence	High; infringement depends on the physical configuration of the marketed connector
Doctrine-of-equivalents potential	Possible, but highly specific geometry may limit equivalence arguments

The absence of material or manufacturing limitations increases breadth in one respect. The patent can potentially cover different elastomers and molding processes. The detailed T-shaped, H-shaped, groove, projection, and differential-thickness requirements narrow the claims in another respect.

What design-arounds could reduce infringement risk?

Potential design-around strategies include:

Using a threaded, welded, ultrasonic, adhesive, or overmolded connector instead of a snap-fit groove-and-projection structure.
Using a membrane with a uniform radial flange thickness.
Replacing the T-shaped flange with a flat annular gasket, radial bead, dovetail profile, or non-annular retaining structure.
Positioning the membrane entirely within one connector half rather than at the interface between two sections.
Using a membrane that does not create a generally H-shaped profile after installation.
Using a rigid support ring with a separate pierceable septum.
Using a valve or slit membrane that does not have the claimed dish-shaped penetrable section.
Capturing the membrane by an axial shoulder rather than by radial flange compression.
Eliminating elastic deformation of the flange and relying on a separate sealing element.

A design-around must be assessed against every limitation of the asserted claim. Avoiding only the T-shaped profile, for example, may not be sufficient if the patent owner asserts another claim based on the connector’s snap-fit geometry.

What FDA regulatory status applies to this patent?

US Patent 8,118,802 concerns a medical-fluid-container connector and self-sealing membrane. It does not claim:

A pharmaceutical active ingredient;
A drug formulation;
A biologic;
A therapeutic method;
A dosage regimen; or
A pharmaceutical manufacturing process.

FDA approval of a product using the connector would therefore be handled under the applicable medical-device regulatory pathway, device classification, quality-system requirements, and product-specific submission. Patent protection does not establish FDA clearance or approval.

The patent should not be expected to appear in the FDA Orange Book. Orange Book listings generally concern patents submitted for approved drug products, active ingredients, formulations, methods of use, and related pharmaceutical protection. A connector patent of this type is outside the ordinary Orange Book listing framework.[2]

When does US Patent 8,118,802 lose exclusivity?

The patent issued on February 21, 2012. The ordinary US patent term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory considerations.[1]

The exact expiration date cannot be established from the supplied claim text alone. The controlling record is the USPTO patent data for:

Earliest effective nonprovisional filing date;
Patent-term adjustment;
Any terminal disclaimer;
Maintenance-fee status;
Reinstatement events; and
Relevant priority or continuation relationships.

Because this is a device patent, Hatch-Waxman drug exclusivity periods do not apply. There is no drug-market exclusivity period tied to the patent itself.

Are Paragraph IV, biosimilar, or generic challenges relevant?

Paragraph IV challenges

Paragraph IV certification applies to abbreviated new drug applications involving patents listed for an FDA-approved drug. The claims supplied here cover a medical connector and membrane, not a drug product. A Paragraph IV challenge is therefore not the ordinary mechanism for contesting this patent.

Biosimilar risk

Biosimilar applicants challenge biologic patents under the Biologics Price Competition and Innovation Act. The patent does not claim a biologic product, biologic formulation, or biologic method of treatment. Biosimilar risk is not applicable.

Generic medical-device competition

Competitors could enter the market with a device that performs the same function while using a different connector or membrane architecture. The relevant risks are patent infringement, regulatory clearance, procurement requirements, quality-system compliance, and customer qualification rather than ANDA substitution.

What litigation, settlements, and licensing issues affect the patent?

The supplied claims do not identify any:

Patent-infringement complaint;
Paragraph IV notice;
Settlement agreement;
Covenant not to sue;
License;
Cross-license;
Assignment restriction; or
Royalty obligation.

Patent claims cannot establish whether a later litigation or transaction exists. Any freedom-to-operate review should examine the USPTO assignment record, maintenance-fee record, continuation applications, related patents, and federal court docket history. The commercial risk may also depend on unasserted continuation claims directed to the same membrane, connector, assembly method, or container system.

How does this patent compare with competing medical-connector patent categories?

Patent category	Typical protected subject matter	Relationship to US 8,118,802
Piercing septum patents	Needle-penetrable and resealable membranes	Adjacent, but generally broader or differently focused
Luer-connector patents	Male/female fittings, lock structures, and fluid interfaces	Separate connector category
Needleless-valve patents	Internal valves, split septa, and flow-control mechanisms	May overlap at the access interface
Container-port patents	Port geometry, weldable bodies, and bag integration	Potentially complementary
Snap-fit connector patents	Groove, projection, latch, and retention structures	Closest structural category
Elastomer formulation patents	Silicone, thermoplastic elastomer, or rubber compositions	Complementary material protection
Manufacturing patents	Molding, assembly, sterilization, and quality-control methods	Potentially separate barriers
Container-system patents	Bag, port, membrane, cap, and access-device combinations	May create layered protection

The principal competitive question is whether a rival product uses a two-piece connector with a captured annular membrane. If it does, the patent is more relevant. If the rival uses an integrated molded port, a valve cartridge, or a threaded retaining ring, the patent’s direct relevance declines.

What geographic coverage does the patent provide?

US Patent 8,118,802 provides enforceable rights in the United States only. Any international protection would require separate patents or national-stage rights in jurisdictions such as Europe, Canada, Japan, China, or Australia.

US patent rights can reach:

Manufacture in the United States;
Use in the United States;
Sale or offer for sale in the United States;
Importation into the United States; and
Certain induced or contributory infringement conduct.

Foreign manufacture followed by importation into the United States can create US infringement exposure if the imported product practices the claimed structure. Foreign sales require separate jurisdictional analysis.

Key Takeaways

US Patent 8,118,802 is a medical-device patent covering a self-sealing membrane and a two-section snap-fit connector.
Claim 1 focuses on the membrane, including the T-shaped flange and its clamping arrangement.
Claim 9 focuses on the connector, including the peripheral groove, peripheral projection, snap-in effect, and accommodation of an H-shaped membrane.
Claims 2-8 and 10-17 add elastic deformation, dish-shaped geometry, differential thickness, annular volumes, and membrane-placement limitations.
The patent does not claim a drug, biologic, formulation, treatment method, or pharmaceutical manufacturing process.
Orange Book listing, Paragraph IV litigation, biosimilar substitution, and Hatch-Waxman exclusivity are not applicable to the supplied claims.
The strongest design-around options involve changing the retention mechanism, flange profile, membrane position, or sealing architecture.
Exact patent expiration and current enforceability require the USPTO term, maintenance, assignment, and continuation records.
The commercial risk is highest for medical-fluid containers using a captured annular septum within a two-piece snap-fit connector.

FAQs About US Patent 8,118,802

Does US Patent 8,118,802 cover a medical fluid bag?

It does not broadly claim the entire bag. The supplied claims focus on the connector and self-sealing membrane associated with a medical-fluid container.

Does a product infringe if it has only a T-shaped membrane flange?

Not necessarily. The independent claims also require specific connector placement or connector architecture. A T-shaped membrane used in a materially different connector may avoid literal infringement.

Does the patent cover a threaded connector?

The supplied claims require a peripheral groove and cooperating peripheral projection that achieve a snap-in effect. A purely threaded connector may avoid the literal scope of claim 9, subject to the full claim language and equivalents analysis.

Can the patent block a needleless access valve?

Only if the accused valve or connector satisfies every limitation of an asserted claim. Functional similarity alone does not establish infringement.

Is the patent relevant to IV-drug manufacturers?

It may be relevant where an IV-drug manufacturer, contract manufacturer, or medical-device supplier uses a connector incorporating the claimed membrane and snap-fit architecture. It does not independently protect the drug formulation or drug approval.

References

United States Code. (2023). 35 U.S.C. §§ 154, 271, 282.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Patent and Trademark Office. (2012). US Patent No. 8,118,802, “Self-sealing membrane and connector for a medical fluid container,” claims 1-17.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	102 23 560	May 27, 2002

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	469630	⤷ Start Trial
Australia	2003208752	⤷ Start Trial
Brazil	0311342	⤷ Start Trial
Brazil	PI0311342	⤷ Start Trial
Canada	2487551	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,118,802

Summary for Patent: 8,118,802